Sarepta Therapeutics experienced a 36% stock drop after disclosure of a third patient death linked to its gene therapies this year. The latest fatality involved a 51-year-old treated with SRP-9004 in the Phase I DISCOVERY trial for limb girdle muscular dystrophy (LGMD), succumbing to acute liver failure. This follows two deaths reported in Duchenne muscular dystrophy patients receiving Elevidys®. Sarepta declined FDA's request to pause Elevidys shipments to ambulant populations, citing no new safety signals. The company simultaneously paused SRP-9004 development for most LGMD candidates.